These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2005-000295-41 Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynaud´s... 2010-04-07 due-trials
Reported results 2005-001596-34 Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia 2012-07-11 due-trials
Ongoing 2005-003156-35 Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study not-yet-due
Reported results 2005-003271-21 Doppelblinde, prospektive, randomisierte, monozentrische, placebo-kontrollierte Pilotstudie zur Wirksamkeit und Sicherheit von Moxifloxacin in der Prophylaxe der Bakteriämie nach Hochdosis-Chemotherap... 2008-12-17 due-trials
Reported results 2005-003516-29 Prospective, randomized, double-blinded clinical trial on remifentanil for analgesia and sedation of ventilated neonates and infants 2010-04-11 due-trials
Exempt, with results Terminated 2005-004139-23 An open-label, non-randomized phase I/II trial of neoadjuvant radio-immunochemotherapy with cetuximab and 5-FU for advanced rectal cancer not-yet-due
Reported results 2005-005393-73 A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and to A... 2010-10-18 due-trials
Reported results Terminated 2005-005612-24 PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA EMMA-1 (ERBITUX FOR MULTIPLE MYELOMA) 2010-06-26 due-trials
Reported results 2006-001936-30 A phase II dose escalation study of caspofungin in patients with invasive aspergillosis 2009-10-26 due-trials
Reported results Terminated 2007-000224-41 A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransferas... 2010-09-15 due-trials
Exempt, with results 2007-000233-18 Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom 2012-06-19 not-yet-due
Not reported 2007-001573-28 Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial. 2014-10-28 due-trials
Reported results 2007-002824-13 Prospective, placebo-controlled blinded clinical trial to study the efficacy of orally administered Glucose 20% for relieving pain during nasopharyngeal suctioning in preterm infants > 1500g under CP... 2010-07-17 due-trials
Reported results 2007-003187-22 Clinical trials for adults HD18 for advanced stages Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; treatment stratification by means of FDG-PET Therapi... 2019-07-18 due-trials
Reported results 2007-003467-48 A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma 2013-11-17 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-004474-24 HD 16 for early stages: treatment optimization trial in the first-line treatment of early stage Hodgkin lymphoma; treatment stratification by means of FDG-PET. 2020-12-29 bad-data
Reported results 2007-005920-34 HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET 2020-03-21 due-trials
Reported results 2007-007587-21 Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic l... 2018-01-01 due-trials
Reported results 2008-000896-30 Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks 2012-06-21 due-trials
Not reported 2008-001421-34 Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leuke... 2014-05-29 due-trials
Reported results 2008-008896-32 Memory, Ageing, and the Cholinergic System a combined fMRI and PET study 2014-05-07 due-trials
Reported results Terminated 2009-010700-28 GRANITE-1 - Granulocyte-transfusions for patients with febrile neutropenia Granulozytentransfusionen bei Patienten mit febriler Neutropenie (GRANITE) 2015-12-02 due-trials
Reported results 2009-012607-26 MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanc... 2013-12-13 due-trials
Exempt 2009-012957-39 A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia 2015-02-12 not-yet-due
Reported results 2009-015217-52 Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - Pilot trial on treatment of patients with primary hyperoxaluria type I with pyridoxal-phosphate 2012-09-19 due-trials
Exempt, with results 2010-021086-73 HD-R3i - A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or re... 2018-12-31 not-yet-due
Reported results 2010-022058-18 A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF CYCLOPHOSPHAMIDE AS SOLE GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-CY) 2013-11-18 due-trials
Reported results 2010-022180-35 Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma 2015-04-22 due-trials
Reported results 2011-000911-26 Heart rate control after acute myocardial infarct 2014-02-24 due-trials
Not reported 2011-001795-19 STATIN RECAPTURE THERAPY BEFORE CORONARY ARTERY BYPASS GRAFTING (ACRONYM: START-CABG TRIAL) 2020-04-27 due-trials
Reported results 2011-003473-29 Trial on treatment with inhaled furosemide of preterm and term neonates with transient tachypnoea Inhalatives Furosemid bei Frühgeborenen und Neugeborenen mit Transitorischer Tachypnoe 2015-07-09 due-trials
Ongoing 2011-004593-29 Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma not-yet-due
Listed as ongoing, but also has a completion date 2011-004698-98 A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk pateints with chr... 2021-01-14 bad-data
Reported results 2011-005082-21 Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphoma Targeted BEACOPP Varianten für Patienten mit Erstdiagnose eines fortgeschrittenen klassischen Hodgkin ... 2016-10-15 due-trials
Not reported 2011-005628-16 FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients Gewichtsreduktion bei Adipositas unter der Therapie mit Bromocriptin in Abhängigkeit vom FTO-Genotyp 2015-06-03 due-trials
Reported results 2011-005655-13 A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or - amplification or - mutation. 2016-06-09 due-trials
Reported results 2011-005797-32 Effentora® for Dyspnoea (EffenDys) - Fentanyl buccal tablet (FBT) for the relief of episodic dyspnoea (ED) in cancer patients: an open label, randomized, morphine-controlled, crossover, phase II trial 2014-10-29 due-trials
Reported results 2012-002887-29 Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab 2015-01-26 due-trials
Reported results 2012-003696-18 Effect of a preinterventional calorie restriction on renal function after contrast agent exposition in patients at risk. Einfluss einer präinterventionellen kalorienreduzierten Diät auf die Nierenf... 2016-10-07 due-trials
Listed as ongoing, but also has a completion date 2013-000577-77 EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION ACRONYM: SABATO (Staphylococcus aureus Bacteremia Antibiotic Treatment Options) 2020-03-31 bad-data
Reported results Terminated 2013-002036-24 A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer 2016-09-15 due-trials
Reported results 2013-002737-38 A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations 2020-02-29 due-trials
Reported results Terminated 2013-003048-21 CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR) Kontrolle der intestinalen Kolonisi... 2017-05-31 due-trials
Ongoing 2013-003211-22 A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients wi... not-yet-due
Reported results 2013-003369-33 JeRiCHO (JAK-inhibition in recurrent classical Hodgkin Lymphoma): A phase II, open-label, prospective, non-randomized, multicenter clinical trial with the JAK-inhibitor ruxolitinib in patients with re... 2019-06-30 due-trials
Ongoing 2013-003990-89 Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II trial- Brentuksimabivedotiini vai B-CAP hoito iäkkä... not-yet-due
Reported results Terminated 2013-004481-34 RANDOMIZED PHASE 2 TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 ... 2016-10-28 due-trials
Reported results 2014-000569-35 A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 ... 2019-03-29 due-trials
Ongoing 2014-000580-40 A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed by ... not-yet-due
Ongoing 2014-000582-47 A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by ... not-yet-due
Reported results 2014-000590-39 A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumu... 2020-02-06 due-trials
Reported results 2014-004036-19 GHSG-AFM13 An open-label, randomized, multicenter phase II trial with AFM13 in patients with relapsed or refractory Hodgkin Lymphoma GHSG-AFM13 Eine offene, randomisierte, multizentrische Phase II ... 2020-01-31 due-trials
Ongoing 2014-005130-55 HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparision of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD. not-yet-due
Reported results Terminated 2015-000568-32 Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation 2019-09-30 due-trials
Reported results 2015-003128-30 Phase II trial of the Btk-inhibitor Ibrutinib in patients with relapsed nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL) Phase II-Studie mit dem Btk-Inhibitor Ibrutinib zur Behandlung des re... 2020-05-20 due-trials
Ongoing 2015-004936-36 A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus... not-yet-due
Ongoing 2016-002626-37 Nivolumab and AVD in earlystage unfavorable classical Hodgkin lymphoma - A GHSG randomized, multicenter phase II trial Nivolumab und AVD für Patienten mit klassischem Hodgkin Lymphom im intermediär... not-yet-due
Ongoing 2016-003334-25 A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition ... not-yet-due
Ongoing 2017-003133-28 A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab), acalabrutinib (ACP-196) and ABT-199 ... not-yet-due
Ongoing 2017-003221-15 PROSPEKTIV RANDOMISIERTE, MULTIZENTRISCHE STUDIE ZUM VERGLEICH DER EINER RADIKALEN HYSTEREKTOMIE NACH NEOADJUVANTER CHEMOTHERAPIE VERSUS EINER PRIMÄREN RADIOCHEMOTHERAPIE BEI PATIENTINNEN MIT EINEM ZE... not-yet-due
Ongoing 2017-003334-82 Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - An international multicenter Phase II trial not-yet-due
Ongoing 2017-004883-37 Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients (NB2015-LR) not-yet-due
Ongoing 2018-000399-13 A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced NSCLC harbouring FGFR genetic alterations after relapse of standard therapy not-yet-due
Ongoing 2018-000873-59 Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma Konsolidierungstherapie mit Brentuximab Vedotin nach allogener ... not-yet-due
Ongoing 2018-002492-17 A prospective, open-label, multicentre Phase-II-Trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK Inhibitor, plus tislelizumab (BGB-A317), a PD-1 Inhibitor, for treatment of ... not-yet-due
Ongoing 2018-003048-22 A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal ad... not-yet-due
Ongoing 2018-003270-27 A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine fol-lowed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and ve-neto... not-yet-due
Ongoing 2019-000914-12 Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors Gazyvaro (Obinutuzumab) als zielgerichtete Therapie gegen Tumorwachstum fördernde, regulatorische B-Zellen bei soliden Tumoren not-yet-due
Ongoing 2019-002036-90 A randomized, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of subcutaneous Dupilumab in localized scleroderma Randomisierte, Placebo kontrollierte klinische Phase... not-yet-due
Ongoing 2019-002734-37 Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folinic ... not-yet-due
Ongoing 2019-002930-35 Phase II trial of TisaGenlecleucel in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma not-yet-due
Ongoing 2019-003854-99 A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients... not-yet-due
Ongoing 2019-003856-35 Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA) Daratumumab als Primärtherapie bei nichttransplantat... not-yet-due
Ongoing 2020-002788-80 An explorative study to assess the safety, tolerability, and efficacy of AZD4831 in the treatment of pulmonary arterial hypertension (PAH) (MPO-PAH) Explorative Studie zur Bewertung der Sicherheit,... not-yet-due
Exempt 2020-003503-34 A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals Eine Phase-1/2a-Studie der intrav... 2021-08-11 not-yet-due
Ongoing 2020-004360-26 A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS WI... not-yet-due
Exempt 2020-004448-27 A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals Eine Phase-1/2a-Studie zur inhalative... 2021-09-23 not-yet-due